AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1948120 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous chemotherapy with 25 mg/m2 of 4-epirubicin intravenously for 18 weeks after surgical castration.
Number of subjects: 145
Study 1948120 — intervention group
Group type: COMPARATOR
Intervention: Hormonal therapy with surgical castration and long-term administration of flutamide without initial chemotherapy.
Number of subjects: 145
Study 6842023 — intervention group
Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine (DEC) therapy
Number of subjects: 20
Study 31960396 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatherapy (20-min inhalation of essential oil every night for 4 weeks)
Number of subjects: 84
Study 31960396 — intervention group
Group type: COMPARATOR
Intervention: Control (20-min inhalation of sweet almond oil every night for 4 weeks)
Number of subjects: 84
Study 31815509 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 85
Study 31815509 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT and MI
Number of subjects: 85
Study 31815509 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT
Number of subjects: 85
Study 31815509 — intervention group
Group type: EXPERIMENTAL
Intervention: MI-CBT
Number of subjects: 85
Study 30115084 — intervention group
Group type: EXPERIMENTAL
Intervention: Reducing portion sizes of foods available in cafeterias by at least 10% from targeted categories (main meals, sides, desserts, cakes).
Number of subjects: 6
Study 30115084 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group not explicitly mentioned).
Number of subjects: 6
Study 27012778 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton-Pump Inhibitors (PPIs)
Number of subjects: 3752
Study 27012778 — intervention group
Group type: COMPARATOR
Intervention: Low-dose aspirin
Number of subjects: 3752
Study 27012778 — intervention group
Group type: COMPARATOR
Intervention: High-dose aspirin
Number of subjects: 3752
Study 25089271 — intervention group
Group type: EXPERIMENTAL
Intervention: Adhesive glue
Number of subjects: 102
Study 25089271 — intervention group
Group type: COMPARATOR
Intervention: Traditional suturing
Number of subjects: 102
Study 22739394 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine (50 mg), Stavudine (6 mg), Lamivudine (30 mg) in fixed dose combination tablet (Triomune Baby)
Number of subjects: 16
Study 19469798 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium-titanyl-phosphate (KTP) laser
Number of subjects: 14
Study 19469798 — intervention group
Group type: COMPARATOR
Intervention: Electrodesiccation
Number of subjects: 14
Study 17855332 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief counselling intervention (N = 442)
Number of subjects: 906
Study 17855332 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 906
Study 14678081 — intervention group
Group type: COMPARATOR
Intervention: SR 49059 (0, 25, 75, or 200 mg)
Number of subjects: 16
Study 14678081 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin (10 pmol/kg)
Number of subjects: 16
Study 14678081 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (50 pmol/kg)
Number of subjects: 16
Study 12224974 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracisional clindamycin
Number of subjects: 1030
Study 12224974 — intervention group
Group type: COMPARATOR
Intervention: Buffered lidocaine with epinephrine without clindamycin (Control)
Number of subjects: 1030
Study 9675622 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 600 mg three times a day with 125 mg MK-0591 twice a day
Number of subjects: 12
Study 9675622 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen 600 mg three times a day with placebo for MK-0591
Number of subjects: 12
Study 9675622 — intervention group
Group type: COMPARATOR
Intervention: MK-0591 125 mg twice a day with placebo for ibuprofen
Number of subjects: 12
Study 9675622 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (Ibuprofen and MK-0591)
Number of subjects: 12
Study 9675622 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9972889 — intervention group
Group type: EXPERIMENTAL
Intervention: Common carotid-subclavian artery bypass (CSB)
Number of subjects: 40
Study 9972889 — intervention group
Group type: EXPERIMENTAL
Intervention: Subclavian-carotid transposition (SCT)
Number of subjects: 40
Study 2651767 — intervention group
Group type: EXPERIMENTAL
Intervention: DST with cyclosporin A (group I)
Number of subjects: 50
Study 2651767 — intervention group
Group type: COMPARATOR
Intervention: DST alone (group II)
Number of subjects: 50
Study 318897 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture with electrically stimulated needles
Number of subjects: 12
Study 318897 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture with needles inserted to avoid recognized acupuncture points
Number of subjects: 12
Study 318897 — intervention group
Group type: COMPARATOR
Intervention: Control session (without needles)
Number of subjects: 12
Study 318897 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture on the epigastrium
Number of subjects: 12
Study 31560794 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpaste containing 0.3% triclosan + 2.0% PVM/MA copolymer + 1450 ppm fluoride (Test)
Number of subjects: 88
Study 31560794 — intervention group
Group type: COMPARATOR
Intervention: Toothpaste containing 1450 ppm fluoride (Control)
Number of subjects: 88
Study 31276981 — intervention group
Group type: EXPERIMENTAL
Intervention: ET + Bev
Number of subjects: 749
Study 31276981 — intervention group
Group type: COMPARATOR
Intervention: ET
Number of subjects: 749
Study 29192318 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-talker speech masker
Number of subjects: 84
Study 29192318 — intervention group
Group type: COMPARATOR
Intervention: speech-spectrum noise
Number of subjects: 84
Study 25451581 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenting intervention for problem-eaters
Number of subjects: 201
Study 25451581 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control for problem-eaters
Number of subjects: 201
Study 25451581 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-reported meal length concern
Number of subjects: 201
Study 24238679 — intervention group
Group type: EXPERIMENTAL
Intervention: Video intervention group (5 minutes from the Play Nicely program)
Number of subjects: 312
Study 24238679 — intervention group
Group type: EXPERIMENTAL
Intervention: Handout group ('Pulling the Plug on TV Violence')
Number of subjects: 312
Study 24238679 — intervention group
Group type: COMPARATOR
Intervention: Primary control group (standard primary care)
Number of subjects: 312
Study 24238679 — intervention group
Group type: COMPARATOR
Intervention: Alternative control group (program about obesity prevention)
Number of subjects: 312
Study 21664510 — intervention group
Group type: EXPERIMENTAL
Intervention: Theory-based Interactive Postpartum Sexual Health Education Program
Number of subjects: 250
Study 21664510 — intervention group
Group type: COMPARATOR
Intervention: Pamphlet only
Number of subjects: 250
Study 21664510 — intervention group
Group type: COMPARATOR
Intervention: Routine education
Number of subjects: 250
Study 19801228 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% sodium hypochlorite (NaOCl)
Number of subjects: 54
Study 19801228 — intervention group
Group type: COMPARATOR
Intervention: 2% chlorhexidine (CHX) gel
Number of subjects: 54
Study 16682611 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal GTN (5 mg)
Number of subjects: 18
Study 16682611 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 18
Study 15642960 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with sulfadoxine-pyrimethamine plus artesunate
Number of subjects: 453
Study 15642960 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling about what to do if a patient vomits
Number of subjects: 453
Study 11320018 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial medication (n = 307)
Number of subjects: 607
Study 11320018 — intervention group
Group type: COMPARATOR
Intervention: Initial surgery (trabeculectomy, n = 300)
Number of subjects: 607
Study 9263611 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipriflavone (600 mg/day, T.D.D.) with 500 mg/day of calcium
Number of subjects: 39
Study 9263611 — intervention group
Group type: COMPARATOR
Intervention: Placebo with 500 mg/day of calcium
Number of subjects: 39
Study 8426770 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular pertussis vaccine (DTaP)
Number of subjects: 100
Study 8426770 — intervention group
Group type: COMPARATOR
Intervention: Whole cell pertussis vaccine (DTwP)
Number of subjects: 100
Study 3723990 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin (15 mg/m2, 4 times per 48 h)
Number of subjects: 0
Study 29232172 — intervention group
Group type: EXPERIMENTAL
Intervention: PEGPH20 plus nab‐paclitaxel/gemcitabine (PAG)
Number of subjects: 279
Study 29232172 — intervention group
Group type: COMPARATOR
Intervention: nab‐paclitaxel/gemcitabine (AG)
Number of subjects: 279
Study 27460675 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month multi-component behavioural change intervention
Number of subjects: 156
Study 27460675 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 156
Study 24621155 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 plus oxaliplatin (OXS regimen)
Number of subjects: 94
Study 24621155 — intervention group
Group type: COMPARATOR
Intervention: S-1 alone
Number of subjects: 94
Study 22499961 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative intra-aortic balloon pump (n=359, 15.3% of high-risk patients)
Number of subjects: 2348
Study 22499961 — intervention group
Group type: COMPARATOR
Intervention: No preoperative intra-aortic balloon pump (n=1989, 84.7% of high-risk patients)
Number of subjects: 2348
Study 22499961 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative intra-aortic balloon pump
Number of subjects: 2348
Study 21077043 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous blood purification (CBP) treatment (CVVH)
Number of subjects: 63
Study 21077043 — intervention group
Group type: COMPARATOR
Intervention: No continuous blood purification (no CVVH)
Number of subjects: 63
Study 18316700 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical coherence tomography (OCT)
Number of subjects: 263
Study 18316700 — intervention group
Group type: COMPARATOR
Intervention: Stereoscopic fundus photographs (FP)
Number of subjects: 263
Study 15772062 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training on cycle ergometers three times per week for 15 weeks
Number of subjects: 53
Study 15772062 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 53
Study 12502214 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallstones present
Number of subjects: 1173
Study 12502214 — intervention group
Group type: EXPERIMENTAL
Intervention: Impacted stones
Number of subjects: 1173
Study 10048679 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin suspension for 5 days
Number of subjects: 168
Study 10048679 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanate for 10 days (for those <5 years)
Number of subjects: 168
Study 10048679 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin estolate suspension (for those >=5 years)
Number of subjects: 168
Study 10048679 — intervention group
Group type: COMPARATOR
Intervention: Healthy control children (no treatment)
Number of subjects: 168
Study 7670281 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal XI HTF (modified HTF containing EDTA and glutamine but devoid of glucose and phosphate)
Number of subjects: 0
Study 7670281 — intervention group
Group type: COMPARATOR
Intervention: Basal HTF (HTF containing EDTA and glutamine)
Number of subjects: 0
Study 7670281 — intervention group
Group type: COMPARATOR
Intervention: Regular HTF
Number of subjects: 0
Study 2289214 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg twice a day for 21 days
Number of subjects: 20
Study 2289214 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 2289214 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 20
Study 383024 — intervention group
Group type: EXPERIMENTAL
Intervention: IV salbutamol
Number of subjects: 0
Study 383024 — intervention group
Group type: COMPARATOR
Intervention: IV aminophylline
Number of subjects: 0
Study 383024 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Number of subjects: 0
Study 30620389 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 4
Study 30620389 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 4
Study 27624622 — intervention group
Group type: COMPARATOR
Intervention: Neladenoson bialanate 30 mg single dose
Number of subjects: 42
Study 27624622 — intervention group
Group type: COMPARATOR
Intervention: Neladenoson bialanate 10 mg for 7 days
Number of subjects: 42
Study 27624622 — intervention group
Group type: COMPARATOR
Intervention: Neladenoson bialanate 20 mg for 7 days
Number of subjects: 42
Study 27624622 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 7 days
Number of subjects: 42
Study 26251661 — intervention group
Group type: EXPERIMENTAL
Intervention: Psycho education during three sessions of one-hour
Number of subjects: 60
Study 26251661 — intervention group
Group type: COMPARATOR
Intervention: Control group (no psycho education)
Number of subjects: 60
Study 24355056 — intervention group
Group type: EXPERIMENTAL
Intervention: DOiT program
Number of subjects: 20
Study 24355056 — intervention group
Group type: COMPARATOR
Intervention: Control schools
Number of subjects: 20
Study 20682612 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral N-acetylcysteine (NAC) with intravenous hydration
Number of subjects: 40
Study 20682612 — intervention group
Group type: COMPARATOR
Intervention: Intravenous hydration only
Number of subjects: 40
Study 19246588 — intervention group
Group type: EXPERIMENTAL
Intervention: Prandial strategy (three premeal doses of insulin lispro targeting 2-h postprandial blood glucose <7.5 mmol/l)
Number of subjects: 1115
Study 19246588 — intervention group
Group type: COMPARATOR
Intervention: Basal strategy (NPH twice daily or insulin glargine once daily targeting fasting/premeal blood glucose <6.7 mmol/l)
Number of subjects: 1115
Study 19246588 — intervention group
Group type: EXPERIMENTAL
Intervention: Prandial strategy
Number of subjects: 1115
Study 19246588 — intervention group
Group type: COMPARATOR
Intervention: Basal strategy
Number of subjects: 1115
Study 16893526 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 73
Study 16893526 — intervention group
Group type: COMPARATOR
Intervention: Taste-matched placebo
Number of subjects: 73
Study 15146410 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-dosage etanercept (25 mg twice weekly) plus anakinra (100 mg/day)
Number of subjects: 244
Study 15146410 — intervention group
Group type: COMPARATOR
Intervention: Etanercept only (25 mg twice weekly)
Number of subjects: 244
Study 15146410 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-dosage etanercept (25 mg once weekly) plus anakinra (100 mg/day)
Number of subjects: 244
Study 11260442 — intervention group
Group type: EXPERIMENTAL
Intervention: Didactic alcohol education programme
Number of subjects: 154
Study 11260442 — intervention group
Group type: EXPERIMENTAL
Intervention: Didactic input plus skills-based training
Number of subjects: 154
Study 11260442 — intervention group
Group type: COMPARATOR
Intervention: Control group (traditional medical school)
Number of subjects: 154
Study 9408807 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (20 mg once daily for 15 days) with terfenadine (60 mg twice daily for 8 days)
Number of subjects: 12
Study 9408807 — intervention group
Group type: COMPARATOR
Intervention: Terfenadine (60 mg twice daily for 8 days) alone
Number of subjects: 12
Study 7969324 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative nutritional support (intravenous solution enriched with 35% branched-chain amino acids, dextrose, and lipid emulsion for 14 days)
Number of subjects: 124
Study 7969324 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative nutritional support
Number of subjects: 124
Study 7969324 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 124
Study 3297129 — intervention group
Group type: EXPERIMENTAL
Intervention: 13-cis-retinoic acid 20 mg/d if marrow blasts ≤ 5% or cytosine arabinoside 10 mg/d subcutaneously on 6 d/week if marrow blasts 6-30%, retinoic acid added after 12 weeks
Number of subjects: 98
Study 3297129 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving conventional supportive therapy
Number of subjects: 98
Study 3297129 — intervention group
Group type: EXPERIMENTAL
Intervention: 13-cis-retinoic acid with cytosine arabinoside in non-sideroblastic patients with ≤ 5% blasts
Number of subjects: 98
Study 31972315 — intervention group
Group type: COMPARATOR
Intervention: YKL‐40 percentile category 91‐100%
Number of subjects: 94665
Study 30022571 — intervention group
Group type: EXPERIMENTAL
Intervention: isCGM group (26 participants, blinded for SMBG, insulin dosing based on isCGM)
Number of subjects: 46
Study 30022571 — intervention group
Group type: COMPARATOR
Intervention: SMBG group (20 participants, blinded for isCGM, insulin dosing based on SMBG)
Number of subjects: 46
Study 30022571 — intervention group
Group type: EXPERIMENTAL
Intervention: isCGM group (26 participants)
Number of subjects: 46
Study 27222271 — intervention group
Group type: EXPERIMENTAL
Intervention: CEP-26401 (0.02 to 5 mg single dose; 0.02 to 0.5 mg once daily multiple dosing)
Number of subjects: 0
Study 27222271 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26476367 — intervention group
Group type: EXPERIMENTAL
Intervention: bivalent OPV (bOPV)
Number of subjects: 975
Study 26476367 — intervention group
Group type: EXPERIMENTAL
Intervention: IPV
Number of subjects: 975
Study 26476367 — intervention group
Group type: COMPARATOR
Intervention: f-IPV
Number of subjects: 975
Study 23850070 — intervention group
Group type: EXPERIMENTAL
Intervention: Scapular repositioning with active cervical rotation technique in addition to conventional physiotherapy
Number of subjects: 23
Study 23850070 — intervention group
Group type: COMPARATOR
Intervention: Conventional physiotherapy (microwave diathermy, submaximal isometrics, and ergonomic advice)
Number of subjects: 23
Study 20504165 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-valent pneumococcal conjugate vaccine (7vPnC) with 1 mg of CPG 7909 adjuvant
Number of subjects: 97
Study 20504165 — intervention group
Group type: COMPARATOR
Intervention: Phosphate-buffered saline (control)
Number of subjects: 97
Study 18357436 — intervention group
Group type: EXPERIMENTAL
Intervention: VTEVC‐compensation
Number of subjects: 9
Study 18357436 — intervention group
Group type: EXPERIMENTAL
Intervention: VTplet‐compensation
Number of subjects: 9
Study 18357436 — intervention group
Group type: COMPARATOR
Intervention: No compensation
Number of subjects: 9
Study 16670616 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin 62.5 microg
Number of subjects: 10
Study 16670616 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin 125 microg
Number of subjects: 10
Study 16670616 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin 250 microg
Number of subjects: 10
Study 16670616 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 12651666 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine infusion
Number of subjects: 20
Study 12651666 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline infusion
Number of subjects: 20
Study 10648327 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine, 2 microg. kg(‐1). min(‐1)
Number of subjects: 20
Study 10648327 — intervention group
Group type: COMPARATOR
Intervention: Placebo IV infusion (Control)
Number of subjects: 20
Study 9289428 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnancy Induced Hypertension (PIH) group
Number of subjects: 63
Study 9289428 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy patients)
Number of subjects: 63
Study 1900223 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of coronary collateral vessels (group A, n = 51)
Number of subjects: 125
Study 1900223 — intervention group
Group type: COMPARATOR
Intervention: Absence of coronary collateral vessels (group B, n = 74)
Number of subjects: 125
Study 6094448 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime 1 g intravenous at the induction of anaesthesia, the beginning of the resection, 4 and 8 h later (Group A)
Number of subjects: 217
Study 6094448 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime 1 g intravenous at the induction of anaesthesia, the beginning of the resection, 4 and 8 h later, associated with ornidazole or metronidazole 0.5 g intravenous at the induction of anaesthesia and 0.5 g intravenous with the last injection of cefotaxime (Group B)
Number of subjects: 217
Study 6094448 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime following the same regimen as groups A and B and metronidazole orally 0.5 tds 3 days before surgery (Group C)
Number of subjects: 217
Study 31124023 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderated private Facebook group (N=72)
Number of subjects: 103
Study 31124023 — intervention group
Group type: COMPARATOR
Intervention: Self-directed intervention materials without additional support (N=31)
Number of subjects: 103
Study 31124023 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (N=103)
Number of subjects: 103
Study 31124023 — intervention group
Group type: EXPERIMENTAL
Intervention: Facebook group (N=72)
Number of subjects: 103
Study 28089142 — intervention group
Group type: EXPERIMENTAL
Intervention: Low mean arterial pressure (MAP) (40‐60 mmHg; n = 5)
Number of subjects: 10
Study 28089142 — intervention group
Group type: EXPERIMENTAL
Intervention: High mean arterial pressure (MAP) (60‐80 mmHg; n = 5)
Number of subjects: 10
Study 28089142 — intervention group
Group type: COMPARATOR
Intervention: Conventional monitoring of rSO2 by NIRS
Number of subjects: 10
Study 25830503 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based HealthyPast50 program
Number of subjects: 278
Study 25830503 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control condition
Number of subjects: 278
Study 23475451 — intervention group
Group type: COMPARATOR
Intervention: Enhanced treatment as usual (N=97) including education about blood‐borne diseases and referrals for testing and vaccinations
Number of subjects: 202